Changes in intestinal flora of mice induced by rEg.P29 epitope peptide vaccines.


Journal

Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460

Informations de publication

Date de publication:
Nov 2023
Historique:
revised: 20 10 2023
received: 20 06 2023
accepted: 26 10 2023
medline: 30 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: ppublish

Résumé

Cystic echinococcosis (CE), a zoonotic parasitic disease caused by Echinococcus granulosus, remains a public health and socioeconomic issue worldwide, making its prevention and treatment of vital importance. The aim of this study was to investigate changes in the intestinal microbiota of mice immunized with three peptide vaccines based on the recombinant antigen of E. granulosus, P29 (rEg.P29), with the hope of providing more valuable information for the development of vaccines against CE. Three peptide vaccines, rEg.P29 The intestinal microbiota analysis at both immunization time points revealed that Firmicutes, Bacteroidota, and Verrucomicrobiota were the predominant flora at the phylum level, while at the genus level, Akkermansia, unclassified_Muribaculaceae, Lachnospiraceae_NK4A136_group, and uncultured_rumen bacterium were the dominant genera. Some probiotics in the intestines of mice were significantly increased after immunization with the peptide vaccines, such as Lactobacillus_taiwanensis, Lactobacillus_reuteri, Lachnospiraceae_NK4A136_group, Bacteroides_acidifaciens, and so forth. Meanwhile, some harmful or conditionally pathogenic bacteria were decreased, such as Turicibacter sanguinis, Desulfovibrio_fairfieldensis, Clostridium_sp, and so forth, most of which are associated with inflammatory or infectious diseases. Kyoto Encyclopaedia of Genes and Genomes enrichment analysis revealed that the differential flora were enriched in multiple metabolic pathways, primarily biological systems, human diseases, metabolism, cellular processes, and environmental information processing. In this study, we comprehensively analyzed and compared changes in the intestinal microbiota of mice immunized with three peptide vaccines as well as their related metabolic pathways, providing a theoretical background for the development of novel vaccines against E. granulosus.

Identifiants

pubmed: 38018604
doi: 10.1002/iid3.1082
pmc: PMC10664826
doi:

Substances chimiques

Epitopes 0
Recombinant Proteins 0
Vaccines, Subunit 0
Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1082

Subventions

Organisme : Ningxia Key R&D Program
ID : 2021BEG03088
Organisme : National Natural Science Foundation of China
ID : 32060805
Organisme : Ningxia Natural Science Foundation
ID : 2022AAC03703

Informations de copyright

© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

Références

Res Vet Sci. 2021 Mar;135:517-522
pubmed: 33246571
FASEB J. 2023 Apr;37(4):e22819
pubmed: 36848174
Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12672-12677
pubmed: 31182571
Front Immunol. 2021 Oct 15;12:746585
pubmed: 34721416
Immunity. 2014 Sep 18;41(3):478-492
pubmed: 25220212
Acta Trop. 2010 Apr;114(1):1-16
pubmed: 19931502
Gut Microbes. 2020 Nov 1;11(6):1713-1728
pubmed: 32564657
Eur Cytokine Netw. 1999 Sep;10(3):365-72
pubmed: 10477393
Nutrients. 2022 Jun 17;14(12):
pubmed: 35745257
Am J Clin Nutr. 2017 Nov;106(5):1274-1286
pubmed: 28877893
Acta Trop. 2022 Feb;226:106252
pubmed: 34808118
Zoonoses Public Health. 2019 Dec;66(8):889-899
pubmed: 31529690
Front Immunol. 2023 Feb 03;14:1131057
pubmed: 36817419
World J Hepatol. 2016 Oct 8;8(28):1169-1181
pubmed: 27729953
Eur Rev Med Pharmacol Sci. 2023 Mar;27(6):2671-2678
pubmed: 37013785
Syst Appl Microbiol. 2005 Jul;28(5):405-14
pubmed: 16094867
Arch Med Res. 2017 Nov;48(8):690-700
pubmed: 29290328
Cells. 2022 Dec 25;12(1):
pubmed: 36611884
World J Gastroenterol. 2015 Feb 14;21(6):1691-702
pubmed: 25684933
Lancet Infect Dis. 2007 Jun;7(6):385-94
pubmed: 17521591
Sci Rep. 2015 Jul 23;5:12371
pubmed: 26201558
Microbiome. 2021 May 26;9(1):122
pubmed: 34039418
Front Microbiol. 2021 Dec 09;12:794746
pubmed: 34956162
Acta Biochim Biophys Sin (Shanghai). 2009 Jan;41(1):79-85
pubmed: 19129953
Nat Commun. 2020 Oct 6;11(1):5015
pubmed: 33024120
Nutrients. 2017 Sep 15;9(9):
pubmed: 28914794
Pharmaceutics. 2021 Jan 26;13(2):
pubmed: 33530627
Bioimpacts. 2018;8(1):39-52
pubmed: 29713601
J Nutr Biochem. 2018 Nov;61:111-128
pubmed: 30196243
Front Immunol. 2022 Feb 08;13:773276
pubmed: 35211114
Acta Parasitol. 2022 Dec;67(4):1594-1602
pubmed: 36048399
Langenbecks Arch Surg. 2003 Sep;388(4):209-17
pubmed: 12937989
Mol Cell Probes. 2002 Oct;16(5):341-50
pubmed: 12477438
Microbiol Immunol. 2020 Jan;64(1):23-32
pubmed: 31595527
PLoS Negl Trop Dis. 2020 Aug 10;14(8):e0008519
pubmed: 32776936
Transbound Emerg Dis. 2021 May;68(3):1080-1096
pubmed: 32762075
Vet Res Commun. 2016 Jun;40(2):73-9
pubmed: 27094043
Front Microbiol. 2018 Nov 29;9:2890
pubmed: 30555437
BMJ. 2012 Jun 11;344:e3866
pubmed: 22689886
Adv Parasitol. 2006;61:443-508
pubmed: 16735171
Zhonghua Yi Xue Za Zhi. 2002 Feb 10;82(3):176-9
pubmed: 11953154
J Infect Dis. 1997 Jan;175(1):218-21
pubmed: 8985225
Nature. 1989 Apr 13;338(6216):585-7
pubmed: 2648160
Front Microbiol. 2023 Mar 08;14:1140498
pubmed: 36970663
Vaccines (Basel). 2023 Feb 23;11(3):
pubmed: 36992108
Front Cell Infect Microbiol. 2020 Apr 30;10:177
pubmed: 32426296
J Immunol. 1971 Dec;107(6):1656-62
pubmed: 4330459
Front Vet Sci. 2022 Jan 13;8:778789
pubmed: 35097041
Mol Biochem Parasitol. 2000 Feb 5;105(2):177-84
pubmed: 10693741
Microbiome. 2019 Feb 19;7(1):28
pubmed: 30782206
Nature. 2013 Dec 19;504(7480):446-50
pubmed: 24226770
Gut Microbes. 2022 Jan-Dec;14(1):2027853
pubmed: 35129072
Int J Syst Evol Microbiol. 2009 Aug;59(Pt 8):2064-8
pubmed: 19605711
Science. 2018 Mar 9;359(6380):1151-1156
pubmed: 29590046
Immunol Rev. 2014 Jul;260(1):206-20
pubmed: 24942691
Clin Microbiol Rev. 2007 Oct;20(4):593-621
pubmed: 17934076
Acta Pharm Sin B. 2022 Aug;12(8):3298-3312
pubmed: 35967282
J Med Microbiol. 2018 Mar;67(3):423-431
pubmed: 29458526

Auteurs

Tingting Zhang (T)

School of Clinical Medicine, Ningxia Medical University, Yinchuan, China.
Key Laboratory of Common Infectious Disease Prevention and Control in Ningxia, Yinchuan, China.

Yongxue Lv (Y)

Key Laboratory of Common Infectious Disease Prevention and Control in Ningxia, Yinchuan, China.
School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, China.

Yinqi Zhao (Y)

Key Laboratory of Common Infectious Disease Prevention and Control in Ningxia, Yinchuan, China.
Science and Technology Center of Ningxia Medical University, Yinchuan, China.

Jihui Yang (J)

Key Laboratory of Common Infectious Disease Prevention and Control in Ningxia, Yinchuan, China.
Science and Technology Center of Ningxia Medical University, Yinchuan, China.

Bingshuo Qian (B)

General Hospital of Ningxia Medical University, Yinchuan, China.

Yazhou Zhu (Y)

Key Laboratory of Common Infectious Disease Prevention and Control in Ningxia, Yinchuan, China.

Wei Zhao (W)

Key Laboratory of Common Infectious Disease Prevention and Control in Ningxia, Yinchuan, China.
School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, China.

Mingxing Zhu (M)

Key Laboratory of Common Infectious Disease Prevention and Control in Ningxia, Yinchuan, China.
Science and Technology Center of Ningxia Medical University, Yinchuan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH